S-1, Oxaliplatin

DRUG4 trials

Sponsors

Yodogawa Christian Hospital, Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo,, Ruijin Hospital

Conditions

Gastric and Gastroesophageal Junction (GEJ) AdenocarcinomaMetastatic colorectal cancercolorectal liver metastases

Phase 2

S-1 plus Oxaliplatin combination chemotherapy in a stop-and-go fashion for metastatic colorectal cancer

Active, not recruitingJPRN-UMIN000004086

Yodogawa Christian HospitalMetastatic colorectal cancer

Start: 2010-07-01Target: 40Updated: 2026-06-29

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Active, not recruitingNCT04208347

Ruijin HospitalGastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Start: 2019-12-18End: 2027-12-01Target: 580Updated: 2026-01-23

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Active, not recruitingNCT06693128

Ruijin HospitalGastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Start: 2024-11-21End: 2027-12-31Target: 80Updated: 2026-01-28

Unknown Phase

A phase I/II triral of S-1 plus L-OHP for colorectal cancer liver metastases after hepatic resection

Active, not recruitingJPRN-UMIN000006396

Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo,colorectal liver metastases

Start: 2011-09-01Target: 55Updated: 2026-06-29

Related Papers

PDPN+ cancer-associated fibroblasts correlate with the neoadjuvant immunotherapy response in gastric cancer

APL Bioengineering2025-08-281 citations

LRRC25 Is a Potential Biomarker for Predicting Immunotherapy Response in Patients with Gastric Cancer.

2025-02-171 citations

Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol

BMJ Open2024-02-016 citations

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer.

2023-01-03163 citations

Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma

Annals of Translational Medicine2020-12-0117 citations

Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial

European Journal of Cancer2020-03-1159 citations